Associations of statin use with 30-day adverse outcomes among 4 801 406 US Veterans with and without SARS-CoV-2: an observational cohort study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
18 03 2022
Historique:
entrez: 19 3 2022
pubmed: 20 3 2022
medline: 26 3 2022
Statut: epublish

Résumé

To estimate associations of statin use with hospitalisation, intensive care unit (ICU) admission and mortality at 30 days among individuals with and without a positive test for SARS-CoV-2. Retrospective cohort study. US Veterans Health Administration (VHA). All veterans receiving VHA healthcare with ≥1 positive nasal swab for SARS-CoV-2 between 1 March 2020 and 10 March 2021 (cases; n=231 154) and a comparator group of controls comprising all veterans who did not have a positive nasal swab for SARS-CoV-2 but who did have ≥1 clinical lab test performed during the same time period (n=4 570 252). Associations of: (1) any statin use, (2) use of specific statins or (3) low-intensity/moderate-intensity versus high-intensity statin use at the time of positive nasal swab for SARS-CoV-2 (cases) or result of clinical lab test (controls) assessed from pharmacy records with hospitalisation, ICU admission and death at 30 days. We also examined whether associations differed between individuals with and without a positive test for SARS-CoV-2. Among individuals who tested positive for SARS-CoV-2, statin use was associated with lower odds of death at 30 days (OR 0.81 (95% CI 0.77 to 0.85)) but not with hospitalisation or ICU admission. Associations were similar comparing use of each specific statin to no statin. Compared with low-/moderate intensity statin use, high-intensity statin use was not associated with lower odds of ICU admission or death. Over the same period, associations of statin use with 30-day outcomes were significantly stronger among individuals without a positive test for SARS-CoV-2: hospitalisation OR 0.79 (95% CI 0.77 to 0.80), ICU admission OR 0.86 (95% CI 0.81 to 0.90) and death 0.60 (95% CI 0.58 to 0.62; p for interaction all <0.001). Associations of statin use with lower adverse 30-day outcomes are weaker among individuals who tested positive for SARS-CoV-2 compared with individuals without a positive test, indicating that statins do not exert SARS-CoV-2 specific effects.

Identifiants

pubmed: 35304400
pii: bmjopen-2021-058363
doi: 10.1136/bmjopen-2021-058363
pmc: PMC8889446
doi:

Substances chimiques

Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e058363

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

PLoS One. 2021 Jul 15;16(7):e0254635
pubmed: 34264974
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
Arch Intern Med. 1998 Sep 14;158(16):1789-95
pubmed: 9738608
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):258-259
pubmed: 32347925
Eur Heart J Cardiovasc Pharmacother. 2022 Feb 16;8(2):157-164
pubmed: 33135047
Int J Nurs Stud. 2020 Sep;109:103372
pubmed: 31227204
Postgrad Med J. 2021 Feb 4;:
pubmed: 33541927
Arch Med Sci. 2021 Feb 10;17(3):579-595
pubmed: 34025827
Epidemiology. 2010 May;21(3):383-8
pubmed: 20335814
Mayo Clin Proc Innov Qual Outcomes. 2021 Apr;5(2):442-446
pubmed: 33748678
BMJ Open. 2020 Dec 4;10(12):e044421
pubmed: 33277291
Pharmacol Rep. 2021 Jun;73(3):769-780
pubmed: 33608850
Diabetes Metab. 2021 Mar;47(2):101202
pubmed: 33091555
Popul Health Metr. 2006 Apr 10;4:2
pubmed: 16606453
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471
Am J Kidney Dis. 2016 Aug;68(2):229-239
pubmed: 27066930
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004876
pubmed: 16856068
Int J Epidemiol. 2016 Dec 1;45(6):1887-1894
pubmed: 28089956
J Rural Health. 2010 Fall;26(4):301-9
pubmed: 21029164
Semin Thromb Hemost. 2021 Jun;47(4):392-399
pubmed: 33482680
Int J Epidemiol. 2006 Apr;35(2):337-44
pubmed: 16368725
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Ann Med. 2021 Dec;53(1):874-884
pubmed: 34096808
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1613-1615
pubmed: 32882643
Med Care. 2017 Sep;55 Suppl 9 Suppl 2:S9-S15
pubmed: 28806361
Nutr Metab Cardiovasc Dis. 2021 Jun 7;31(6):1662-1670
pubmed: 33838992
Am J Manag Care. 1999 Apr;5(4):437-44
pubmed: 10387383
JAMA. 2021 Jun 22;325(24):2424-2425
pubmed: 34081086

Auteurs

Pandora L Wander (PL)

Veterans Affairs Puget Sound Health Care System Seattle Division, Seattle, Washington, USA lwander@u.washington.edu.
Department of Medicine, University of Washington, Seattle, Washington, USA.

Elliott Lowy (E)

Veterans Affairs Puget Sound Health Care System Seattle Division, Seattle, Washington, USA.
Department of Health Systems and Population Health, University of Washington, Seattle, Washington, USA.

Lauren A Beste (LA)

Veterans Affairs Puget Sound Health Care System Seattle Division, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.

Luis Tulloch-Palomino (L)

Veterans Affairs Puget Sound Health Care System Seattle Division, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.

Anna Korpak (A)

Veterans Affairs Puget Sound Health Care System Seattle Division, Seattle, Washington, USA.

Alexander C Peterson (AC)

Veterans Affairs Puget Sound Health Care System Seattle Division, Seattle, Washington, USA.

Steven E Kahn (SE)

Veterans Affairs Puget Sound Health Care System Seattle Division, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.

Goodarz Danaei (G)

Department of Global Health and Population, Harvard School of Public Health, Boston, Massachusetts, USA.

Edward J Boyko (EJ)

Veterans Affairs Puget Sound Health Care System Seattle Division, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH